Direct and Indirect Impact of 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Invasive Pneumococcal Disease (IPD) Among Children and Adults in the U.S.

Monica Farley, Emory University
T Pilishvili
R Gierke
W Schaffner
A Thomas
A Reingold
L Harrison
R Lynfield
SM Zansky
S Petit

Only first 10 authors above; see publication for full author list.

Journal Title: Open Forum Infectious Diseases
Volume: Volume 4, Number suppl_1
Publisher: (publisher) | 2017, Pages S66-S67
Type of Work: Article
Publisher DOI: 10.1093/ofid/ofx162.158
Permanent URL: https://pid.emory.edu/ark:/25593/s6f6c

Final published version: http://dx.doi.org/10.1093/ofid/ofx162.158

Accessed November 26, 2017 3:00 AM EST
2491. Murine Typhus: a Common Cause of Acute Febrile Illness with Potential for Serious Complications

Zeehan Azaal, MD; Sunand Kallumamda, MD; Feng Wang, MD; Vagish S. Hemmige, MD; and Daniel Musher, MD. FIDSA. 1Department of Family and Preventive Medicine, McAllen Family Medicine Residency Program, The University of Texas Rio Grande Valley, McAllen, Texas; 2Section of Infectious Diseases, Baylor College of Medicine, Houston, Texas; 3Baylor College of Medicine, Houston, Texas.

Session: 277. Global Infections
Saturday, October 7, 2017: 2:00 PM

Background. Individual cases and outbreaks of murine typhus have been documented in South Texas. We report 90 cases from Hidalgo County, Texas, enumerating complications and comparing results in children and adults.

Methods. We reviewed records of 101 patients in three hospitals in Hidalgo County, Texas, who had positive typhus serology (IgG or IgM titer ≥1:128) during 2014–2016 and were categorized as suspected, probable or confirmed murine typhus cases in accord with CDC definitions. We excluded 11 cases because a concurrent infection may have confounded our tabulation of manifestations or there was insufficient information to make a clinical diagnosis.

Results. The majority presented with typical typhus: fever, headache, myalgias and fatigue. Rash, thrombocytopenia and elevated hepatic transaminases were frequent (Table). Clinical complications in 25 cases (28%) caused a less typical syndrome, including bronchiolitis, pneumonia, pancreatitis, cholecystitis, mesenteric adenitis, myositis, rhabdomyolysis, meningitis and septic shock. Procalcitonin was >0.5 in 10 of 14 (71%) cases. Once the diagnosis was suspected, patients were treated with doxycycline with a rapid response in every case. Generally fever disappeared within 24–36 hours of the first dose.

Conclusion. Murine typhus is a common endemic infection in South Texas. Although most patients had a typical syndrome, the disease is multisystem, and complications appeared in 28% of cases. Procalcitonin was usually elevated. Rats and oppossums are common reservoirs for Rickettsia typhi, and a search for cases of murine typhus may be warranted in other parts of the US as well, so that treatment with doxycycline can be begun promptly.

Disclosures. All authors: No reported disclosures.

Table: Symptoms, signs, laboratory findings

<table>
<thead>
<tr>
<th>Symptom</th>
<th>&lt; 18 Age</th>
<th>&gt;18 Age</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fever (temperature &gt;105.4)</td>
<td>36/36 (100%)</td>
<td>53/54 (98%)</td>
</tr>
<tr>
<td>Myalgia</td>
<td>15/20 (75%)</td>
<td>21/24 (88%)</td>
</tr>
<tr>
<td>Headache</td>
<td>23/32 (72%)</td>
<td>37/46 (80%)</td>
</tr>
<tr>
<td>Signs</td>
<td>&lt;0.01</td>
<td>0.44</td>
</tr>
<tr>
<td>Rash</td>
<td>18/36 (50%)</td>
<td>16/31 (52%)</td>
</tr>
<tr>
<td>Labs</td>
<td>&lt;0.01</td>
<td>0.12</td>
</tr>
</tbody>
</table>

WBC count < 6,000          | 11/36(31%)  | 10/54(19%)  |
| Platelets < 120,000       | 12/36(33%)  | 37/46(69%)  |
| Blutirubin ≤1.5           | 3/36(8%)   | 14/54(26%)  |
| AST >50                  | 25/58(69%)  | 51/64(84%)  |

*Comparing pediatric vs. adult cases.

2492. Direct and Indirect Impact of 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Invasive Pneumococcal Disease (IPD) Among Children and Adults in the US.

Tamara Pilishvili, MPH; Ryan Gierke, MPH; Monica Farley, MD, FIDSA; William Schaffner, MD, FIDSA, FSHEA; Ann Thomas, MD, MPH; Arthur Reingold, MD, FIDSA; Lee Harrison, MD; Ruth Lynfield, MD, FIDSA; Shelley M. Zandek, PhD; Scott, MS (MPH); Lisa Miller, MD, MSPH; Joan Baumback, MD, MPH, MS; Bernard, Farley, PhD; and Cynthia Whitney, MD, MPH, FIDSA. 1National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; 2Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia; 3Department of Medicine, Emory University School of Medicine and Atlanta VA Medical Center, Atlanta, Georgia; 4Vanderbilt University School of Medicine, Nashville, Tennessee; 5Oregon Public Health Division, Portland, Oregon; 6University of California – Berkeley, Berkeley, California; 7University of Pittsburgh, Pittsburgh, Pennsylvania; 8Minnesota Department of Health, St. Paul, Minnesota; 9New York State Department of Health, Albany, New York; 10Connecticut Emerging Infections Program, New Haven, Connecticut; 11Preventive Medicine Residency Program, University of Colorado School of Public Health, Aurora, Colorado; 12New Mexico Department of Health, Santa Fe, New Mexico; 13Centers for Disease Control and Prevention, Atlanta, Georgia.

Session: 278. Pneumococcal and Pertussis Vaccines
Saturday, October 7, 2017: 2:00 PM

Background. In February 2010, PCV13 was introduced for routine use among children < 5 years. In June 2012, PCV13 was recommended for use in series with 23-valent polysaccharide vaccine (PPSV23) for adults ≥19 years with selected medical conditions, and in August 2014, for all adults ≥65 years. We evaluated the direct and indirect effects of PCV13 6 years post-introduction on invasive pneumococcal disease (IPD).

Methods. IPD cases (isolation of pneumococcus from sterile sites) were identified among residents of Active Bacterial Core surveillance (ABCs) sites during July 2007–June 2016. Isolates were serotyped by Quelling, PCR, or whole genome sequencing and classified as PCV13 or non-vaccine type (NVT). Incidence changes were estimated as percent changes (one minus rate ratio) and 95% confidence intervals (95% CI) between pre-PCV13 (2007–2009) and two post-PCV13 periods (July 2014–June 2015 and July 2015–June 2016).

Results. ABCs identified 31,190 IPD cases between 2007 and 2015, with 2,750 cases among children <5 years and 10,930 among those ≥65 years. During the two post-PCV13 periods, overall IPD rates were 35%–62% lower relative to 2007–2009 among all age groups, including <5 years and ≥65 years (Figure). Significant reductions in PCV13-type IPD incidence were observed for all age groups during both post-PCV13 periods, with incidence 84% (95% CI 78, 88%) and 68% (95% CI 63, 73%) lower in 2015–2016 among children < 5 years and adults ≥65 years, respectively. PCV13-type IPD reductions were driven by serotypes 19A and 7F. IPD due to non-vaccine types also declined significantly among children < 5 years (−27%, 95% CI –42, –9%) and adults ≥65 years (−24%, 95% CI –34, –14%). PCV13-type IPD incidence did not differ significantly between the two post-PCV13 periods.

Conclusion. IPD incidence declined among children and adults in the US following PCV13 introduction among children. The lack of difference in PCV13 rates between 2014–2015 and 2015–2016 suggests no measurable early impact of PCV13 introduction among children. The lack of difference in IPD rates among adults ≥65 years may be due to the limited number of cases and the insensitivity of ABCs surveillance to hospitalised pneumococcal disease.

Disclosures. All authors: No reported disclosures.
2493. Invasive Pneumococcal Disease in Massachusetts Children 6 Years Following Introduction of PCV13

Inci Aldirirm, MD MSc1; Brent Little, PhD2; Stephen I. Pelton, MD3; Pediatric Infectious Diseases, Emory University, Atlanta, Georgia; 1Pediatric Infectious Diseases, Boston University, Boston, Massachusetts and, 2Boston University Schools of Medicine and Public Health, Boston, Massachusetts

Session: 278. Pneumococcal and Pertussis Vaccines
Saturday, October 7, 2017: 2:00 PM

Background. A second generation 13-valent-pneumococcal conjugate vaccine (PCV13) replaced PCV7 in the childhood immunization schedule in Massachusetts (MA) beginning in April 2010.

Methods. Cases of invasive pneumococcal disease (IPD) in children <18 years of age were detected through an enhanced surveillance system in MA since 2001. All cases in children and Streptococcus pneumoniae (SP) isolates, when available, are submitted to Department of Public Health (MDPH) and parents/physicians are interviewed for confirmation of demographic and clinical data. All available isolates are confirmed as SP serotyped by Quellung reaction.

Results. Three-hundred-thirty-seven IPD cases have been identified in MA children between 4January 4, 2010 and 03.31.2017(Figure). Thirty-five(10.4%) were in children >5 years old. Among children under 2; incidence of IPD was noted in 18. For PCV13 ST, the types of IPD were pneumonia (30.5%) and CNS disease (6.6%). Children with at least one comorbidity were an increasing proportion of cases reaching 37.9% in 2016 (p = 0.004). The overall mortality rate was 4.3%. Isolates from 301 (90.1%) were available for serotyping; vaccine serotypes (VST) were identified in 101 (33.6%) cases [serotype 19A(49 cases), 7F(21 cases), 3(18 cases), 19F (7 cases), 6A(3 cases), serotypes 14, 18C and 5(1 case each)] in the proportion of VST disease declined to 24.1% from 59.2% over 6 years after PCV13 (p < 0.001). Serotype 15B (13.5%), 3F (12.5%) and 22F (12.5%) were the most common nonvaccine serotypes (NVST).

Conclusion. In the post-PCV13-era, IPD is primarily due to NVSTs and disproportionately observed in children with comorbid conditions. In the most recent year (4.1.2016 through 3.31.2017) an increase in incidence was observed in MA children after six years of declining cases following implementation of PCV13.

Disclosures. W. Schaffner, Pfizer: Scientific Advisor, Consulting fee; Merck: Scientific Advisor, Consulting fee; Novavax: Consultant, Consulting fee; Dynavax: Consultant, Consulting fee; Sanofi-pasteur: Consultant, Consulting fee; GSK: Consultant, Consulting fee; Seqirus: Consultant, Consulting fee; L. Harrison, GSK: Scientific Advisor, Consulting fee

2494. Analysis of Invasive Pneumococcal Infections Due to 13-Pneumococcal Conjugate Vaccine Serotypes at 8 US Children’s Hospitals During 2014 to 2016

Sheldon L. Kaplan, MD, FIDSA1; William J. Barson, MD, FPID2; Philaean Ling Lin, MD3; Jesse F. Romero, MD3; John S. Bradley, MD, FIDSA, RPID3; Tina S. Shelnutt, MD, FIDSA4; Laurence B. Givner, MD5; Jill Hoffman, MD5; Kristina Hulten, PhD6 and Edward O. Mason Jr, PhD, FIDSA7; Pediatrics, Baylor College of Medicine and Texas Children’s Hospital, Houston, Texas; 2Nationalwide Children’s Hospital and The Ohio State University College of Medicine, Columbus, Ohio; 3Children’s Hospital of Pittsburgh, Pittsburgh, Pennsylvania; 4University of Arkansas for Medical Sciences, Little Rock, Arkansas; 5Pediatric Infectious Diseases, University of California at San Diego School of Medicine, San Diego, California; 6Northwestern University Feinberg School of Medicine, Chicago, Illinois; 7Wake Forest University School of Medicine, Winston-Salem, North Carolina; 8Children’s Hospital, Los Angeles, Los Angeles, California; 9Baylor College of Medicine and Texas Children’s Hospital, Houston, Texas

Session: 278. Pneumococcal and Pertussis Vaccines
Saturday, October 7, 2017: 2:00 PM

Background. The 13-Valent Pneumococcal Conjugate Vaccine (PCV13) was licensed in 2010 and is directed against serotypes (ST) 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. Details of cases of invasive pneumococcal disease (IPD) due to PCV13 ST since 2010 in the US are sparse. We describe IPD cases due to PCV13 ST seen at 8 US children’s hospitals over years 2014 to 2016 which may aid in understanding why some IPD cases due to these ST have persisted.

Methods. Children with IPD have been prospectively identified at 8 children’s hospitals in the US since 1993. Data from 2014 through 2016 were analyzed. Demographic, clinical data and number and dates of PCV doses were collected on case report forms and isolates were sent to a central laboratory for serotyping. PCV doses are counted if IPD occurred >2 weeks after a dose.

Results. PCV13 ST accounted for 19.7% (271/137) and 26.8% (30/112) and 26% (33/127) of IPD cases in 2014, 2015 and 2016, respectively. ST 3, 19A and 19F accounted for 90% of the PCV13 ST IPD cases. >50% of the children had received ≥2 doses of PCV13 prior to IPD. (Table) Of the 30 children with ≤2 doses of PCV, 15 were >50% of the children had received ≤2 doses of PCV, 15 were of an age at diagnosis for which ≥ 2 doses of PCV was recommended. An underlying condition was noted in 18. For PCV13 ST, the types of IPD were pneumonia (n = 35), mastoiditis (n = 15), bacteraemia (n = 15), meningitis (n = 12) and other sites of infection (n = 9). Whereas the numbers of yearly cases were similar for ST3 (12, 10, 13) and ST19A (8, 8, 6), the numbers for 19F increased slightly (5, 8, 10).

Conclusion. Four to 6 years after PCV13 was introduced, PCV13 ST (especially ST 3, 19A and 19F) accounted for about 25% of IPD in children. For all of the PCV13 ST, over half of these IPD cases occurred in children who had received ≥2 doses of the recommended PCV schedule; 25% of cases occurred in children who had not received any doses but were of the age at diagnosis that at least 2 PCV doses should have been received. Additional PCV13 ST IPD cases may be preventable if the PCV13 schedule is followed as recommended.

Disclosures. S. L. Kaplan, Pfizer: Grant Investigator and Speaker at PCV13 Launch Meeting in China, Research grant and Speaker honorarium; J. S. Bradley, Merck & Co., Inc.: Investigator, Research support

Disclosures. S. I. Pelton, Pfizer: Board Member and Grant Investigator, Consulting fee, Research grant and Speaker honorarium; Merck vaccines: Board Member, Consulting fee and Speaker honorarium; GSK: Board Member, Consulting fee and Speaker honorarium; Seqirus: Board Member, Consulting fee and Speaker honorarium

OFID 2017:4 (Suppl 1) • S67